← Leaderboards
Andras Komaromy
University Of Pennsylvania
$6,828,118
Attributed
$8,121,978
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $696.9K · FY2009–25$1M$750K$500K$250K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,121,978 · 3
By mechanism
R01$8,121,978 · 3
Top collaborators
- Daniel Mark Lipinski4 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- William A. Beltran$14,525,140
- Gustavo David Aguirre$22,398,317
- Trevor M. Penning$29,812,455
- Ian Alexander Blair$30,276,296
- Jerome Frank Strauss$21,625,634
Others in their field
Top investigators on “Design”
- Lawrence Corey · Fred Hutchinson Cancer Center$736,542,541
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$460,267,569
- Jeffrey P Krischer · University Of South Florida$427,700,530
- David R. Weir · University Of Michigan At Ann Arbor$385,316,144
Research focus
DesignAnimal ModelTranslationsCanis FamiliarisBlindnessPreventGene TherapyTransgene ExpressionMediatingAdeno-Associated Viral VectorSafetyBaseAffectGene ExpressionGene ReplacementGene Replacement TherapyRecombinant Adeno-Associated Virus (Raav)MutantFunctional DisorderMutationMissense MutationMolecularDisease PhenotypeInherited
Grant awards (15)
Development of an IOP-lowering gene therapy treatment for glaucoma$629,806
R01 · FY2025 · EY
Development of an IOP-lowering gene therapy treatment for glaucoma$644,048
R01 · FY2024 · EY
Development of an IOP-lowering gene therapy treatment for glaucoma$638,374
R01 · FY2023 · EY
Development of an IOP-lowering gene therapy treatment for glaucoma$675,492
R01 · FY2022 · EY
Therapy development for open-angle glaucomas$608,404
R01 · FY2021 · EY · contact PI
Therapy development for open-angle glaucomas$592,352
R01 · FY2020 · EY · contact PI
Therapy development for open-angle glaucomas$638,082
R01 · FY2019 · EY · contact PI
Therapy development for open-angle glaucomas$691,835
R01 · FY2018 · EY · contact PI
Therapy development for open-angle glaucomas$696,882
R01 · FY2017 · EY · contact PI
Achromatopsia - Disease Mechanisms and Cone-Directed Gene Therapy$398,450
R01 · FY2013 · EY · contact PI
Achromatopsia - Disease Mechanisms and Cone-Directed Gene Therapy$446,171
R01 · FY2012 · EY · contact PI
Achromatopsia - Disease Mechanisms and Cone-Directed Gene Therapy$428,925
R01 · FY2011 · EY · contact PI
Achromatopsia - Disease Mechanisms and Cone-Directed Gene Therapy$441,274
R01 · FY2010 · EY · contact PI
Achromatopsia - Disease Mechanisms and Cone-Directed Gene Therapy$107,615
R01 · FY2010 · EY · contact PI
Achromatopsia - Disease Mechanisms and Cone-Directed Gene Therapy$484,268
R01 · FY2009 · EY · contact PI